# Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia

> **NCT05941585** · NA · COMPLETED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 60 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Mitoxantrone hydrochloride liposome injection30mg/m2
- **DRUG:** HomoharringtonineD1-D7(2mg/m2/day)
- **DRUG:** Venetoclax (d4 100mg/day, d5200mg/day ,d6-d12 400mg/day)
- **DRUG:** Cytarabine(standard-dose:d1-d7100mg/m2/day)
- **DRUG:** Cytarabine(intermediate-dose:d1-d4100mg/m2/day, d5-d7 1g/m2)
- **DRUG:** Mitoxantrone hydrochloride liposome injection24mg/m2

## Key facts

- **NCT ID:** NCT05941585
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-08
- **Primary completion:** 2025-01-17
- **Final completion:** 2025-01-17
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05941585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05941585, "Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05941585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*